American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma

Glavey, Siobhán; Ghobrial, Irène M.

doi:10.1586/17474086.2015.1029449

Cited by 7 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 Smoldering SMM is an intermediate clinical stage between MGUS and MM. It is classified as having high serum or urinary monoclonal protein as well as clonal BM plasma cells in the range of 10-60%, in the absence of additional myelomadefining events 40 such as hypercalcemia, renal insufficiency, anemia, or bone lesions. 41 With the evasion techniques of clonal evolution and drug resistance, MM may progress to an aggressive, bone-marrow independent disease known as plasma cell leukemia (PCL).…”

Section: Pathogenesis Of MMmentioning

confidence: 99%

Multiple myeloma in the marrow: pathogenesis and treatments

Fairfield

Falank

Avery

et al. 2016

Annals of the New York Academy of Sciences

156

133

View full text Add to dashboard Cite

Multiple myeloma (MM) is a B-cell malignancy resulting in osteolytic lesions and fractures. In the disease state, bone healing is limited due to increased osteoclastic and decreased osteoblastic activity, as well as an MM-induced forward-feedback cycle where bone-embedded growth factors further enhance tumor progression as bone is resorbed. Recent work on somatic mutation in MM tumors has provided insight into cytogenetic changes associated with this disease; the initiating driver mutations causing MM are diverse due to the complexity and multitude of mutations inherent in MM tumor cells. This manuscript provides an overview of MM pathogenesis by summarizing cytogenic changes related to oncogenes and tumor suppressors associated with MM, reviewing risk factors, and describing the disease progression from MGUS to overt MM. It also highlights the importance of the bone marrow microenvironment (BMM) in the establishment and progression of MM, as well as associated MM-induced bone disease, and the relationship of the bone marrow to current and future therapeutics. This review highlights why understanding the basic biology of the healthy and diseased BMM is crucial in the quest for better treatments and work toward a cure for genetically diverse diseases such as MM.

show abstract

Section: Pathogenesis Of MMmentioning

confidence: 99%

Multiple myeloma in the marrow: pathogenesis and treatments

Fairfield

Falank

Avery

et al. 2016

Annals of the New York Academy of Sciences

156

133

View full text Add to dashboard Cite

show abstract

“…MGUS has progressed to either smouldering multiple myeloma or multiple myeloma when bone marrow plasma cells exceed 10% [289,313]. Smouldering myeloma is defined by the following two criteria [289].…”

Section: The Plasma Cell Population In Multiple Myelomamentioning

confidence: 99%

“…First, serum IgG or IgA exceeds 30 g/L, urinary monoclonal protein exceeds 0.5 g/24 hours, or clonal bone marrow plasma cells are 10-60%. Second, the absence of myeloma-defining events or amyloidosis is required [313]. Smouldering multiple myeloma has a 10% overall annual risk of progression to multiple myeloma, but this risk varies considerably between patients.…”

Section: The Plasma Cell Population In Multiple Myelomamentioning

confidence: 99%

See 1 more Smart Citation

Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood

Rundgren

Bruserud

Ryningen

et al. 2018

Journal of Immunological Methods

View full text Add to dashboard Cite

show abstract

“…1 Patients with MM have an overall 5-year survival rate of about 45% (high-risk patients within 2 years) and a median survival of 3 to 4 years. 2 Although the use of some novel agents such as immunomodulatory drugs and proteasome inhibitors has prolonged the survival of patients in recent years, patients with MM are still at risk of recurrence and deterioration at any time. 3 Microparticles (MPs) are a group of extracellular vesicles and are shed from the cell surface to the cell surroundings and blood circulation following stimulation.…”

Section: Introductionmentioning

confidence: 99%

The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring

Liu

Tian

Deng

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

Multiple myeloma (MM) is malignant tumor with abnormal proliferation of bone marrow plasma cells. The existing clinical tools used to determine treatment response and tumor relapse are limited in sensitivity. We investigated the CD138+ microparticles (MPs) of MM patients to find out whether MPs could provide a novel means to monitor the malignant cells in MM patients. Our study showed that the levels of MPs were significantly elevated in MM patients. The MP counts in peripheral blood from new diagnosed MM patients were significantly higher than patients in CR and HD. Consist with the total MPs, the number of the PC‐derived MPs (CD138+) increased in BM from MM patients compared with CR and HD. The ratio of the PC‐derived MPs (CD138+) in BM increased in MM patients compared with CR and HD. The correlation test revealed that the CD138+ MPs in BM and PB were all positively correlated with the plasmacyte ratio in bone marrow (BMPC) and the β2‐MG. New diagnosed MM patients and controls were compared, and ROC curves were used to identify cutoff points with optimal sensitivity and specificity concerning the ratios and counts of CD138+ MPs in BM and PB. The AUC of the CD138+ MP counts in BM was 0.767, and in PB was 0.680. The AUC of the CD138+ MP ratios in BM was 0.714, and in PB was 0.666. According to this, the counts of CD138+ MPs in BM showed to be a powerful marker of diagnosis. We demonstrated that CD138+ MPs from the plasma provide support for a potential monitoring biomarker of MM.

show abstract

American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma

Cited by 7 publications

References 21 publications

Multiple myeloma in the marrow: pathogenesis and treatments

Multiple myeloma in the marrow: pathogenesis and treatments

Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood

The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring

Contact Info

Product

Resources

About